CD38 antibody re-treatment in daratumumab-refractory multiple myeloma after time on other therapies.
Perez de Acha O, Reiman L, Jayabalan DS, Walker ZJ, Bosma G, Keller AL, Parzych SE, Abbott D, Idler BM, Ribadeneyra D, Niesvizky R, Forsberg PA, Mark TM, Sherbenou DW.
Perez de Acha O, et al. Among authors: keller al.
Blood Adv. 2023 Nov 14;7(21):6430-6440. doi: 10.1182/bloodadvances.2023010162.
Blood Adv. 2023.
PMID: 37648670
Free PMC article.